• Home
  • About
  • All Companies
    • Recent
    • Summary Lists
  • Contact

Baccuico

  • February 23, 2021
  • New Biotech Startups

Baccuico has developed a proprietary bacterial cultivation platform that combines directed evolution, next generation sequencing, and machine learning to access novel compounds from biological ‘dark matter’.

The company’s Bacterial Community Cultivation platform (BACCU) directs the evolution of unculturable bacteria, so that the bacteria evolve to become culturable in the lab. Once brought into the laboratory, these bacteria can be screened for valuable metabolites.

​Baccuico says that less than 1% of bacteria up until now have been cultured in a laboratory. However using the company’s platform it has been able to boost cultivation rates to around 20%, which has allowed it to start building a library of novel bacterial species for downstream metabolite screening.

The company aims to tackle the antibiotic resistance crisis by discovering novel antibiotic classes targeting some of the most urgent bacterial pathogens, before moving on to broader applications across the medical, agricultural and industrial spaces.

Founded in 2020, Baccuico is based in the UK and is backed angel investors including Jonathan Milner (Founder of Abcam), Lord David Prior (Chairman of the NHS), Peder Holk Neilsen (Former President and CEO of Novozymes), and Leopoldo Zambeletti (Former Head of Healthcare at JP Morgan), among others.


Subscribe for alerts on new companies featured on Startups.Bio


May 24, 2022Aulos Bioscience
Aulos Bioscience aims to revolutionize cancer patient care through the development of pioneering Interleukin-2 therapeutics for the treatment of solid tumor cancers. Interleukin-2 or IL-2 …
May 18, 2022Code Bio
Code Bio is using its novel targeted non-viral delivery platform to develop genetic medicines for serious and life-threatening diseases such as Type 1 Diabetes and …
May 9, 2022Muna Therapeutics
Muna Therapeutics aims to preserve brain function and enhance resilience to neurodegenerative diseases.  The company engages in the discovery and development of novel therapies that …
April 27, 2022Glyphic Biotechnologies
Glyphic Biotechnologies is an MIT spin-out aiming to accelerate the critical but slow step of sequencing new proteins, potentially cutting drug development times down by …
April 24, 2022ImmuneID 
ImmuneID is a precision immunology company that has developed a genome-wide, high-throughput platform to provide an understanding of individual immune responses. ImmuneID's aiSPIRE platform screens billions of …
April 15, 2022Flare Therapeutics
Flare uses a “switch-site based drug discovery approach” to develop a pipeline of therapeutic programs that target pivotal cancer drivers such as transcription factor dysregulation …

Tags:

© Copyright 2022. Startups.Bio, powered by VentureRadar.